论文部分内容阅读
目的观察阿替普酶联合丁苯酞治疗超急性期脑梗死的临床效果。方法将206例超急性期脑梗死患者随机分为观察组和对照组各103例。入院后2组均给予常规治疗,在此基础上对照组给予阿替普酶治疗,观察组在对照组基础上给予丁苯酞氯化钠注射液治疗。观察2组临床疗效、躯体NIHHS评分、家庭社会负担情况及不良反应发生情况。结果观察组总有效率高于对照组;治疗后2组6h、24h及7d的NIHSS评分均低于治疗前,且观察组低于对照组;观察组各家庭负担低于对照组,差异均有统计学意义(P<0.05)。2组均未出现严重不良反应。结论超急性脑梗死在溶栓时间窗内溶栓后及早使用丁苯酞可改善患者生活状况,减轻家庭社会负担,疗效显著,值得临床推广。
Objective To observe the clinical effect of alteplase and butylphthalide in the treatment of hyperacute cerebral infarction. Methods 206 cases of hyperacute cerebral infarction were randomly divided into observation group and control group, 103 cases each. After admission, both groups were given routine treatment. On the basis of this, the control group was treated with alteplase. The observation group was given butylphthalide and sodium chloride injection on the basis of the control group. The clinical efficacy, body NIHHS score, family social burden and adverse reactions were observed in the two groups. Results The total effective rate of the observation group was higher than that of the control group. NIHSS scores of 6h, 24h and 7d after treatment in both groups were lower than those before treatment, and the observation group was lower than the control group. The family burden in the observation group was lower than that in the control group Statistical significance (P <0.05). No serious adverse reactions occurred in both groups. Conclusion The early use of butylphthalide in patients with hyperacute cerebral infarction after thrombolysis can improve the living conditions of the patients and reduce the social burden of the family. The therapy is worthy of clinical promotion.